There are nowadays available treatments for non-small cell lung cancer (NSCLC), which target specific driver mutations and immunotherapies designed to activate the patient’s immune system. While these therapies can be highly beneficial, their effectiveness varies among individuals. Before prescribing targeted therapy for lung cancer patients, it is necessary to conduct biomarker testing.
Comprehensive biomarker testing is performed on patients diagnosed with lung cancer to identify particular mutations or the presence of specific proteins. This is the initial step in Precision Medicine. We make sure patients receive personalized treatment based on biomarker analysis.
In the following section we:
- educate patients on the concept of biomarkers
- illustrate how biomarkers inform treatment decisions for lung cancer
- explain the process of biomarker testing
